Pasar al contenido principal

SUBUNIDADES REGULADORAS DE CANALES DE CL- CLC Y SUS ENFERMEDADES ASOCIADAS LEUCOENCEFALOPATIA MEGALENCEFALICA Y SINDROME DE BARTTER

SAF2012-31486

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2012
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Secretaría de Estado de Investigación, Desarrollo e Innovación
Centro beneficiario UNIVERSIDAD DE BARCELONA
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Megalencephalic leukoencephalopathy with subcortical cysts, A personal biochemical retrospective

  • Estévez, Raúl|||0000-0003-1579-650X
  • Elorza-Vidal, Xabier
  • Gaitan Peñas, Hector|||0000-0001-9797-903X
  • Pérez-Rius, Carla
  • Armand-Ugón, Mercedes|||0000-0002-4069-9915
  • Alonso-Gardón, Marta
  • Xicoy Espaulella, Efren
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Arnedo, Tanit
  • Capdevila-Nortes, Xavier
  • López-Hernández, Tania
  • Montolio, Marisol|||0000-0001-5494-5737
  • Duarri, Anna|||0000-0003-4075-5478
  • Teijido, Oscar|||0000-0002-4600-6972
  • Barrallo Gimeno, Alejandro|||0000-0003-2086-8926
  • Palacín Prieto, Manuel|||0000-0002-8670-293X
  • Nunes Martínez, Virginia|||0000-0002-5747-9310
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare type of leukodystrophy characterized by dysfunction of the role of glial cells in controlling brain fluid and ion homeostasis. Patients affected by MLC present macrocephaly, cysts and white matter vacuolation, which lead to motor and cognitive impairments. To date, there is no treatment for MLC, only supportive care. MLC is caused by mutations in the MLC1 and GLIALCAM genes. MLC1 is a membrane protein with low identity to the Kv1.1 potassium channel and GlialCAM belongs to an adhesion molecule family. Both proteins form a complex with an as-yet-unknown function that is expressed mainly in the astrocytes surrounding the blood-brain barrier and in Bergmann glia. GlialCAM also acts as an auxiliary subunit of the chloride channel ClC-2, thus regulating its localization at cell-cell junctions and modifying its functional properties by affecting the common gate of ClC-2. Recent studies in Mlc1-, GlialCAM- and Clcn2-knockout mice or Mlc1-knockout zebrafish have provided fresh insight into the pathophysiology of MLC and further details about the molecular interactions between these three proteins. Additional studies have shown that GlialCAM/MLC1 also regulates other ion channels (TRPV4, VRAC) or transporters (Na+/K+-ATPase) in a not-understood manner. Furthermore, it has been shown that GlialCAM/MLC1 may influence signal transduction mechanisms, thereby affecting other proteins not related with transport such as the EGF receptor. Here, we offer a personal biochemical retrospective of the work that has been performed to gain knowledge of the pathophysiology of MLC, and we discuss future strategies that may be used to identify therapeutic solutions for MLC patients.